US 12,408,978 B2
Devices and methods for treating lung tumors
Dorin Panescu, San Jose, CA (US); Shashank Raina, Santa Clara, CA (US); Mark Gelfand, New York, NY (US); Mark Leung, Duncan (CA); and Simplicio Velilla, Santa Clara, CA (US)
Assigned to ZIDAN MEDICAL, INC., New York, NY (US)
Filed by Zidan Medical Inc., New York, NY (US)
Filed on Mar. 12, 2024, as Appl. No. 18/602,921.
Application 18/602,921 is a continuation of application No. 17/088,051, filed on Nov. 3, 2020, granted, now 11,925,409.
Application 17/088,051 is a continuation of application No. 16/521,334, filed on Jul. 24, 2019, granted, now 10,842,560, issued on Nov. 24, 2020.
Application 16/521,334 is a continuation of application No. PCT/US2018/049991, filed on Sep. 7, 2018.
Claims priority of provisional application 62/650,246, filed on Mar. 29, 2018.
Claims priority of provisional application 62/631,225, filed on Feb. 15, 2018.
Claims priority of provisional application 62/555,675, filed on Sep. 8, 2017.
Claims priority of application No. 201810310511.1 (CN), filed on Apr. 9, 2018.
Prior Publication US 2024/0252237 A1, Aug. 1, 2024
Int. Cl. A61B 18/14 (2006.01); A61B 18/00 (2006.01); A61B 18/04 (2006.01); A61B 34/20 (2016.01)
CPC A61B 18/1492 (2013.01) [A61B 34/20 (2016.02); A61B 2018/0022 (2013.01); A61B 2018/00541 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/00982 (2013.01); A61B 2018/048 (2013.01); A61B 2018/1425 (2013.01); A61B 2018/1467 (2013.01); A61B 2018/1472 (2013.01); A61B 2034/2051 (2016.02); A61B 2034/2061 (2016.02); A61B 2034/2063 (2016.02); A61B 2218/002 (2013.01); A61B 2218/007 (2013.01)] 32 Claims
OG exemplary drawing
 
1. A method to treat a human patient comprising:
advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient at a target region in the lung,
injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume from the distal portion of the catheter into the target region, wherein the injecting of the conductive hypertonic saline solution injects no more than 20 ml of the conductive hypertonic saline solution into the target region;
delivering energy from the distal portion into the conductive hypertonic saline solution in the target region, wherein the energy heats the conductive hypertonic saline solution in the portion of the airway, and
ablating the target region with the energy delivered from the distal portion.